

Title	Global Burden of Cardiovascular Diseases and Risks, 1990-2022
Author(s)	Mensah, George A.; Fuster, Valentin; Murray, Christopher J.L. et al.
Citation	Journal of the American College of Cardiology. 2023, 82(25), p. 2350-2473
Version Type	АМ
URL	https://hdl.handle.net/11094/93901
rights	© 2023. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc- nd/4.0/
Note	

The University of Osaka Institutional Knowledge Archive : OUKA

https://ir.library.osaka-u.ac.jp/

The University of Osaka

# Global Burden of Cardiovascular Diseases and Risks, 1990-2022

George A. Mensah, MD, Valentin Fuster, MD, PHD, Christopher J. L. Murray, MD, DPhil, Gregory A. Roth, MD, MPH, on behalf of the Global Burden of Cardiovascular Diseases and Risks Collaborators

Funding: Bill and Melinda Gates Foundation, American College of Cardiology Foundation

Disclosures: The contents and views expressed in this report are those of the authors and do not necessarily reflect the official views of the National Institutes of Health, the Department of Health and Human Services, the U.S. Government, or the affiliated institutions. Information about the authors' relationships as they pertain to the contents of this paper will be collected and disclosed prior to publication.

Twitter Handles and Hashtags: #GBDstudy @IHME\_UW @NHLBI\_Translate

Word Count: 1,717 for summary of methods, excluding references and tables

Address for Correspondence: Dr. Gregory A. Roth, Institute for Health Metrics and Evaluation, 3980 15th Ave. NE, Seattle, WA 98195 USA, UW Campus Box #351615. E-mail: rothg@uw.edu

### **Cardiovascular Disease in all Regions** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates by region ranged from 73.6 per 100,000 in High-income Asia Pacific to 432.3 per 100,000 in Eastern Europe in 2022. Global CVD mortality decreased by 34.9% from 1990 to 2022. Ischemic heart disease had the highest global age-standardized DALYs of all diseases at 2,275.9 per 100,000. Intracerebral hemorrhage and ischemic stroke were the next highest CVD causes for age-standardized DALYs. Age-standardized CVD prevalence ranged from 5,881.0 per 100,000 in South Asia to 11,342.6 per 100,000 in Central Asia. High systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 2,564.9 per 100,000 globally. Of all risks, household air pollution from solid fuels had the largest change in attributable age-standardized DALYs from 1990 to 2022 with a 65.1% decrease.




Figure 1. Global map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

194.1 - 228.3 329.5 - 379.6




Figure 2. Global cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	46,358,651	386,947	575.5	4.5	162.5
Ischemic heart disease	315,390,626	9,239,181	3,610.2	108.8	2,275.9
Ischemic stroke	86,661,746	3,542,299	994.5	42.3	819.5
Intracerebral hemorrhage	20,509,587	3,428,876	237.9	39.4	923.8
Subarachnoid hemorrhage	9,281,913	344,872	107.2	4.0	120.7
Hypertensive heart disease	13,052,641	1,353,074	150.9	16.1	292.7
Non-rheumatic calcific aortic valve disease	13,551,699	146,199	156.6	1.8	26.8
Non-rheumatic degenerative mitral valve disease	15,592,046	37,843	177.9	0.5	11.1
Other non-rheumatic valve diseases	12,130	2,033	0.1	<0.1	0.6
Myocarditis	625,129	26,702	7.8	0.3	11.8
Alcoholic cardiomyopathy	554,214	62,661	6.3	0.7	24.6
Other cardiomyopathy	4,715,332	295,751	58.7	3.5	99.3
Pulmonary arterial hypertension	193,710	20,561	2.3	0.2	7.4
Atrial fibrillation and flutter	55,414,434	362,381	637.5	4.5	102.9
Aortic aneurysm	Not estimated	153,118	Not estimated	1.8	34.6
Lower extremity peripheral arterial disease	105,980,247	73,928	1,213.3	0.9	19.6
Endocarditis	438,374	82,402	5.4	1.0	25.8
Other cardiovascular and circulatory diseases	86,722,785	221,797	1,006.1	2.6	118.8

Table 1. Global cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.





Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Global estimate indicated by a triangle, loess line in blue with shaded 95% uncertainty interval.






Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

# **Cardiovascular Disease in Central Asia** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	618,471	2,480	624.3	2.8	119.3
Ischemic heart disease	7,125,865	182,604	8,573.3	268.9	5,135.8
Ischemic stroke	951,108	45,226	1,091.5	69.6	1,330.9
Intracerebral hemorrhage	184,547	34,154	194.0	45.2	1,008.4
Subarachnoid hemorrhage	102,912	4,109	109.7	5.2	147.4
Hypertensive heart disease	71,919	12,724	96.4	19.0	337.4
Non-rheumatic calcific aortic valve disease	117,564	236	147.0	0.3	8.5
Non-rheumatic degenerative mitral valve disease	375,266	246	500.0	0.3	14.7
Other non-rheumatic valve diseases	220	54	0.3	0.1	1.8
Myocarditis	6,279	303	6.8	0.3	12.0
Alcoholic cardiomyopathy	5,279	861	5.5	0.9	32.5
Other cardiomyopathy	54,216	7,598	60.3	8.7	272.5
Pulmonary arterial hypertension	2,208	330	2.3	0.4	13.1
Atrial fibrillation and flutter	424,061	1,571	565.6	2.6	79.6
Aortic aneurysm	Not estimated	1,326	Not estimated	1.8	37.9
Lower extremity peripheral arterial disease	612,533	349	835.5	0.5	13.2
Endocarditis	854	177	0.9	0.2	7.5
Other cardiovascular and circulatory diseases	427,924	2,008	497.1	2.6	90.7

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level



Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

# **Cardiovascular Disease in Central Europe** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Central Europe ranged from 132.6 to 581.4 per 100,000 in 2022; a 4.4 fold difference. CVD mortality decreased by 47.0% from 1990 to 2022. Out of the 21 regions, Central Europe was ranked 2nd in 1990 and 7th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 444.3 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable agestandardized CVD DALYs at 2,963.3 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Year (Count) (Count) (Rate) (Rate) Type (DALYs, Rate) Rheumatic heart disease 63,222 2,976 30.7 1.3 30.7 Ischemic heart disease 12.141.290 338.314 5.430.8 141.8 2,601.9 Ischemic stroke 1,841,834 155,795 853.9 63.1 1,063.1 Intracerebral hemorrhage 193.385 46,002 121.7 20.0 443.8 Subarachnoid hemorrhage 177.955 7.020 108.0 3.4 114.2 356,261 66,782 151.7 444.3 Hypertensive heart disease 27.6 Non-rheumatic calcific 869.200 377.5 49.2 6.517 2.7 aortic valve disease Non-rheumatic degenerative mitral valve disease 677,172 2.486 288.1 11 24.2 Other non-rheumatic valve 1.303 347 0.8 0.2 3.1 diseases 12,887 1.594 11.1 0.8 19.7 Mvocarditis Alcoholic cardiomyopathy 42,646 4,804 25.2 2.4 71.9 20,028 95.7 169.5 Other cardiomyopathy 160.289 8.6 Pulmonary arterial 3 515 445 23 02 61 hypertension Atrial fibrillation and flutter 1.412.498 12.606 6049 5.1 111 8 Aortic aneurysm Not estimated 6,482 Not estimated 2.8 61.7 Lower extremity peripheral 2,227,532 942.2 50.4 7.116 2.9 arterial disease 20.5 6.884 1.351 5.9 0.7 Endocarditis Other cardiovascular and 1,879,255 6,875 951.1 3.1 118.1 circulatory diseases

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in Eastern Europe** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY



Summary: Age-standardized CVD mortality rates among

Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Years Гуре (Count) (Count) (Rate) (Rate) (DALYs, Rate) Rheumatic heart disease 241,126 3,324 73.9 1.0 28.6 Ischemic heart disease 25.389.496 914.066 7.243.7 254.3 4,882.7 Ischemic stroke 3,074,246 348,195 924.7 95.7 1,642.8 Intracerebral hemorrhage 467,843 90,934 159.3 26.4 680.1 154.7 Subarachnoid hemorrhage 317.276 16.751 108.9 5.0 171,771 27,760 46.8 7.7 138.5 Hypertensive heart disease Non-rheumatic calcific 963.872 0.7 19.2 2.470 266.4 aortic valve disease Non-rheumatic degenerative mitral valve disease 949,952 832 259.7 0.2 9.6 Other non-rheumatic valve 395 131 0.2 <0.1 1.3 diseases 17.479 743 77 0.2 8.6 Mvocarditis Alcoholic cardiomyopathy 177,153 38,801 63.6 13.2 521.2 157,875 25,924 76.2 339.9 Other cardiomyopathy 8.9 Pulmonary arterial 7722 117 28 <01 17 hypertension Atrial fibrillation and flutter 2.384.327 19.282 6631 5.3 1199 Aortic aneurysm Not estimated 13,936 Not estimated 4.0 93.8 Lower extremity peripheral 4,018,233 1,099.9 66.3 13.208 3.6 arterial disease 48.1 Endocarditis 9.142 3.058 4.8 1.1 Other cardiovascular and circulatory diseases 2,914,750 16,721 863.9 4.9 164.1

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.





Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

400






Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration


Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington


### **Cardiovascular Disease in Australasia** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY



2022 Age-Standardized CVD Mortality Per 100,000 57.5 - 108.2 259.1 - 287.6 108.3 - 147.4 287.7 - 329.4 147.5 - 194.0 329.5 - 379.6 194.1 - 228.3 379.7 - 441.4 228.4 - 259.0 441.5 - 714.5

Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification





Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Years Туре (Count) (Count) (Rate) (Rate) (DALYs, Rate) Rheumatic heart disease 22,224 638 52.9 1.1 27.1 Ischemic heart disease 1,282,122 29.819 2,380.2 47.4 893.0 Ischemic stroke 322.348 9,651 625.8 14.0 250.4 Intracerebral hemorrhage 41.072 4.199 95.2 6.8 130.1 Subarachnoid hemorrhage 34.529 1,457 80.0 2.7 76.8 33,550 1,606 56.5 2.4 39.8 Hypertensive heart disease Non-rheumatic calcific 198.197 331.3 45.5 2.162 3.2 aortic valve disease Non-rheumatic degenerative mitral valve disease 118,556 373 199.4 0.6 11.7 Other non-rheumatic valve 55 7 0.1 <0.1 0.2 diseases 4.306 73 14.6 0.2 9.0 Mvocarditis Alcoholic cardiomyopathy 12,654 470 27.6 0.9 29.8 1,331 107.7 Other cardiomyopathy 39.079 2.3 62.7 Pulmonary arterial 1192 62 28 01 38 hypertension Atrial fibrillation and flutter 533.587 4.748 918 4 7.0 1498 Aortic aneurysm Not estimated 1,764 Not estimated 2.9 49.6 Lower extremity peripheral 515,310 878.6 23.3 1.056 1.6 arterial disease Endocarditis 4.542 755 9.7 1.3 26.1 Other cardiovascular and 1,018,013 1.335 2.019.0 2.3 152 2 circulatory diseases

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.






Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in High-Income Asia Pacific** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in High-income Asia Pacific ranged from 72.7 to 252.6 per 100,000 in 2022; a 3.5 fold difference. CVD mortality decreased by 64.2% from 1990 to 2022. Out of the 21 regions, High-income Asia Pacific was ranked 20th in 1990 and 21st in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, aortic aneurysm had the highest age-standardized DALYs in 2022 at 79.6 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable agestandardized CVD DALYs at 762.7 per 100,000.






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification





Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Year (Count) (Count) (Rate) (Rate) Type (DALYs, Rate) Rheumatic heart disease 51,813 5,344 15.8 0.7 11.6 Ischemic heart disease 12.020.073 160.226 2.586.8 26.0 581.2 3,765,022 115,125 900.3 15.5 347.4 Ischemic stroke Intracerebral hemorrhage 826.618 55.686 238.1 10.1 249.5 Subarachnoid hemorrhage 685.207 18,210 186.2 3.9 133.5 310,906 58.4 3.0 46.7 Hypertensive heart disease 22,366 Non-rheumatic calcific 1.479.296 285.1 32.5 20.761 2.5 aortic valve disease Non-rheumatic degenerative mitral valve disease 1,970,448 4.122 390.3 05 11.8 Other non-rheumatic valve 326 31 0.1 <0.1 0.2 diseases 27.538 559 15.7 0.2 8.9 Mvocarditis Alcoholic cardiomyopathy 13,218 479 5.0 0.1 4.4 44.0 Other cardiomyopathy 201.378 9.689 81.9 1.7 Pulmonary arterial 9 2 5 9 1.137 30 02 88 hypertension Atrial fibrillation and flutter 2.188.998 18.040 4612 25 681 Aortic aneurysm Not estimated 26,762 Not estimated 4.4 79.6 Lower extremity peripheral 5,112,414 9.5 2.692 951.9 0.4 arterial disease 5.825 24.892 6.8 0.8 14.9 Endocarditis Other cardiovascular and circulatory diseases 3.392.925 5.480 962.4 1.0 71.0

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

#### **Cardiovascular Disease in High-Income North America** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	667,615	6,262	104.0	0.9	22.5
Ischemic heart disease	29,774,092	545,993	4,512.7	75.8	1,572.4
Ischemic stroke	7,310,116	133,791	1,243.8	17.4	392.9
Intracerebral hemorrhage	811,487	64,618	161.1	9.3	217.9
Subarachnoid hemorrhage	424,733	20,234	84.2	3.1	93.3
Hypertensive heart disease	1,030,771	77,701	159.5	11.2	245.2
Non-rheumatic calcific aortic valve disease	2,822,210	26,859	399.9	3.5	51.3
Non-rheumatic degenerative mitral valve disease	3,765,229	4,250	531.1	0.6	16.3
Other non-rheumatic valve diseases	712	78	0.2	<0.1	0.4
Myocarditis	55,489	809	17.3	0.2	11.3
Alcoholic cardiomyopathy	94,817	5,917	18.1	1.0	31.7
Other cardiomyopathy	525,115	23,631	124.8	3.6	95.4
Pulmonary arterial hypertension	8,771	1,888	1.7	0.3	7.5
Atrial fibrillation and flutter	8,517,878	43,337	1,209.9	5.6	161.4
Aortic aneurysm	Not estimated	13,625	Not estimated	2.0	42.2
Lower extremity peripheral arterial disease	12,665,608	12,402	1,784.6	1.7	33.7
Endocarditis	51,368	10,617	10.2	1.6	36.4
Other cardiovascular and circulatory diseases	10,519,632	21,465	1,884.4	3.3	182.8

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level



Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

#### **Cardiovascular Disease in Southern Latin America** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Southern Latin America ranged from 114.9 to 173.6 per 100,000 in 2022; a 1.5 fold difference. CVD mortality decreased by 51.2% from 1990 to 2022. Of the 21 regions, Southern Latin America ranked 13th in 1990 and 16th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, other cardiovascular and circulatory diseases had the highest age-standardized DALYs in 2022 at 281.0 per 100,000. High systolic blood pressure had the largest number of attributable agestandardized CVD DALYs at 1,486.4 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	52,634	1,201	61.0	1.3	26.7
Ischemic heart disease	2,609,524	57,655	2,920.1	62.5	1,287.1
Ischemic stroke	528,575	21,539	615.0	22.7	401.3
Intracerebral hemorrhage	204,460	14,720	253.2	16.4	412.0
Subarachnoid hemorrhage	102,243	3,945	125.9	4.5	144.0
Hypertensive heart disease	98,942	14,678	107.9	15.5	230.0
Non-rheumatic calcific aortic valve disease	244,711	2,972	267.5	3.2	53.0
Non-rheumatic degenerative mitral valve disease	128,886	336	141.0	0.4	9.5
Other non-rheumatic valve diseases	23	7	<0.1	<0.1	0.2
Myocarditis	3,935	87	5.4	0.1	3.7
Alcoholic cardiomyopathy	2,095	172	2.6	0.2	5.9
Other cardiomyopathy	71,655	8,491	97.2	9.3	198.6
Pulmonary arterial hypertension	2,260	132	2.8	0.2	5.7
Atrial fibrillation and flutter	419,791	4,074	459.7	4.3	87.2
Aortic aneurysm	Not estimated	2,380	Not estimated	2.6	55.4
Lower extremity peripheral arterial disease	983,138	567	1,071.6	0.6	14.1
Endocarditis	4,242	1,566	5.6	1.7	41.4
Other cardiovascular and circulatory diseases	1,700,581	8,696	1,970.7	9.5	281.0

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in Western Europe** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Western Europe ranged from 80.2 to 199.9 per 100,000 in 2022; a 2.5 fold difference. CVD mortality decreased by 60.2% from 1990 to 2022. Of the 21 regions, Western Europe ranked 15th in 1990 and 19th in 2022 for agestandardized CVD mortality. After ischemic heart disease and all stroke subtypes, other cardiovascular and circulatory diseases had the highest age-standardized DALYs in 2022 at 166.7 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 977.2 per 100,000.






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification





Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Year Гуре (Count) (Count) (Rate) (Rate) (DALYs, Rate) Rheumatic heart disease 115,044 18,447 14.9 1.6 26.5 Ischemic heart disease 27.188.008 576.481 2.928.5 49.5 957.8 Ischemic stroke 6,280,537 228,785 702.4 17.4 312.8 Intracerebral hemorrhage 795.635 95,176 112.6 8.5 170.5 Subarachnoid hemorrhage 570.991 22,622 84.6 2.3 68.3 1,211,065 115,009 108.9 114.2 Hypertensive heart disease 8.6 Non-rheumatic calcific 4.297.106 61.9 55.830 419.1 4.3 aortic valve disease Non-rheumatic degenerative mitral valve disease 3.167.713 9.420 308.5 0.8 15.4 Other non-rheumatic valve 1.693 298 0.2 <0.1 0.5 diseases 45.972 1.523 9.6 0.2 5.2 Mvocarditis Alcoholic cardiomyopathy 95,734 4,892 14.4 0.6 17.2 2.7 58.5 Other cardiomyopathy 530.824 31.479 86.2 Pulmonary arterial 23 892 1.756 36 02 48 hypertension Atrial fibrillation and flutter 7.681.289 81.522 7497 6.1 1281 Aortic aneurysm Not estimated 29,615 Not estimated 2.7 51.0 Lower extremity peripheral 20,564,688 2,099.2 30.4 17.682 1.4 arterial disease 19.801 94.539 12.7 1.7 31.4 Endocarditis Other cardiovascular and 17.808.574 32.595 2.140.9 3.0 166.7 circulatory diseases

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level



Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

### **Cardiovascular Disease in Andean Latin America** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Andean Latin America ranged from 96.1 to 187.2. per 100,000 in 2022; a 1.9 fold difference. CVD mortality decreased by 39.9% from 1990 to 2022. Out of the 21 regions, Andean Latin America was ranked 21st in 1990 and 18th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 169.3 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 1,230.6 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	457,455	494	656.7	0.8	53.7
Ischemic heart disease	1,070,915	34,037	1,721.7	59.0	1,173.5
Ischemic stroke	469,672	10,679	756.7	19.0	356.2
Intracerebral hemorrhage	99,306	9,357	150.7	15.6	397.3
Subarachnoid hemorrhage	155,742	3,937	242.6	6.3	216.0
Hypertensive heart disease	85,773	5,595	145.0	9.9	169.3
Non-rheumatic calcific aortic valve disease	80,043	391	134.1	0.7	17.1
Non-rheumatic degenerative mitral valve disease	16,939	144	28.4	0.2	6.7
Other non-rheumatic valve diseases	24	4	<0.1	<0.1	0.1
Myocarditis	3,365	39	5.2	0.1	2.4
Alcoholic cardiomyopathy	27	3	<0.1	<0.1	0.1
Other cardiomyopathy	23,166	660	35.9	1.1	39.2
Pulmonary arterial hypertension	1,809	84	2.8	0.1	5.1
Atrial fibrillation and flutter	402,429	2,532	684.4	4.6	111.4
Aortic aneurysm	Not estimated	563	Not estimated	1.0	20.3
Lower extremity peripheral arterial disease	502,546	116	858.6	0.2	7.8
Endocarditis	2,992	221	4.6	0.4	13.6
Other cardiovascular and circulatory diseases	780,772	1,237	1,247.7	2.1	118.8

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.






Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in the Caribbean** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in the Caribbean ranged from 97.3 to 459.2 per 100,000 in 2022; a 4.7 fold difference. CVD mortality decreased by 34.7% from 1990 to 2022. Out of the 21 regions, the Caribbean was ranked 11th in 1990 and 13th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 44.16 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable agestandardized CVD DALYs at 2,605.3 per 100,000.






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification





Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Years Туре (Count) (Count) (Rate) (Rate) (DALYs, Rate) Rheumatic heart disease 261,123 921 540.7 1.8 110.6 Ischemic heart disease 1.659.127 58.168 3,058.2 104.6 2,235.9 Ischemic stroke 490,869 21,153 913.3 38.0 701.9 Intracerebral hemorrhage 105.537 16.704 202.2 30.6 812.9 192.7 Subarachnoid hemorrhage 107.267 2.705 203.4 5.1 101,513 185.4 21.8 441.6 Hypertensive heart disease 12,193 Non-rheumatic calcific 151.0 21.6 83.167 473 0.9 aortic valve disease Non-rheumatic degenerative mitral valve disease 20.214 214 36.9 0.4 12.6 Other non-rheumatic valve 34 10 0.1 <0.1 0.5 diseases 3.162 178 6.5 0.4 21.4 Mvocarditis Alcoholic cardiomyopathy 9,102 1.096 17.2 2.0 62.3 4.2 138.5 Other cardiomyopathy 25.868 2.200 53.5 Pulmonary arterial 1233 106 24 02 116 hypertension Atrial fibrillation and flutter 388 887 2.633 7049 4.6 112 8 Aortic aneurysm Not estimated 1,189 Not estimated 2.2 41.2 Lower extremity peripheral 602,048 1,111 1,087.3 37.5 2.0 arterial disease 2.215 0.9 33.3 Endocarditis 444 4.6 Other cardiovascular and 586.853 2.294 1,101.1 4.3 179.7 circulatory diseases

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level



Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in Central Latin America** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Central Latin America ranged from 109.5 to 329.4 per 100,000 in 2022; a 3.0 fold difference. CVD mortality decreased by 25.1% from 1990 to 2022. Out of the 21 regions, Central Latin America was ranked 19th in 1990 and 14th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 185.0 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable agestandardized DALYs at 1,771.4 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	2,180,136	1,085	818.2	0.4	50.5
Ischemic heart disease	6,773,869	266,503	2,606.2	108.9	2,112.4
Ischemic stroke	2,013,978	47,303	782.1	19.9	369.8
Intracerebral hemorrhage	414,191	34,937	156.5	13.8	339.3
Subarachnoid hemorrhage	515,867	11,313	195.6	4.4	145.5
Hypertensive heart disease	293,297	26,580	119.2	11.1	185.0
Non-rheumatic calcific aortic valve disease	415,329	1,998	163.5	0.8	20.0
Non-rheumatic degenerative mitral valve disease	94,050	918	37.1	0.4	9.0
Other non-rheumatic valve diseases	416	53	0.2	<0.1	0.5
Myocarditis	15,823	219	6.2	0.1	4.0
Alcoholic cardiomyopathy	7,615	473	2.8	0.2	6.3
Other cardiomyopathy	98,861	3,939	40.4	1.6	50.8
Pulmonary arterial hypertension	8,503	223	3.2	0.1	3.2
Atrial fibrillation and flutter	1,830,384	11,672	731.2	5.0	121.3
Aortic aneurysm	Not estimated	3,108	Not estimated	1.3	25.9
Lower extremity peripheral arterial disease	3,237,956	906	1,293.0	0.4	13.0
Endocarditis	11,943	1,309	4.8	0.5	17.6
Other cardiovascular and circulatory diseases	3,451,669	6,319	1,330.6	2.6	131.7

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.






Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in Tropical Latin America** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Tropical Latin America ranged from 157.7 to 201.8 per 100,000 in 2022; a 1.3 fold difference. CVD mortality decreased by 52.6% from 1990 to 2022. Out of the 21 regions, Tropical Latin America was ranked 12th in 1990 and 15th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 245.4 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized DALYs at 1,706.2 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	1,178,179	3,017	492.9	1.2	59.1
Ischemic heart disease	3,706,448	170,497	1,397.5	65.8	1,467.1
Ischemic stroke	2,083,023	77,319	795.6	30.9	545.1
Intracerebral hemorrhage	450,678	46,943	173.2	17.8	462.2
Subarachnoid hemorrhage	394,619	14,180	150.2	5.4	175.8
Hypertensive heart disease	424,780	34,337	166.1	13.6	245.4
Non-rheumatic calcific aortic valve disease	377,483	3,857	143.7	1.5	31.1
Non-rheumatic degenerative mitral valve disease	113,713	1,459	43.2	0.6	14.2
Other non-rheumatic valve diseases	477	73	0.2	<0.1	0.8
Myocarditis	16,568	379	7.1	0.2	6.3
Alcoholic cardiomyopathy	19,642	983	7.5	0.4	13.6
Other cardiomyopathy	276,933	14,154	118.0	5.6	147.0
Pulmonary arterial hypertension	6,328	709	2.5	0.3	9.3
Atrial fibrillation and flutter	2,055,246	14,553	787.2	5.9	136.0
Aortic aneurysm	Not estimated	8,909	Not estimated	3.4	74.5
Lower extremity peripheral arterial disease	2,903,792	3,707	1,118.7	1.5	30.9
Endocarditis	14,833	2,771	6.6	1.1	33.9
Other cardiovascular and circulatory diseases	3,621,645	9,064	1,403.2	3.6	158.2

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

#### **Cardiovascular Disease in North Africa and Middle East** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in North Africa and Middle East ranged from 132.5 to 578.7 per 100,000 in 2022; a 4.4 fold difference. CVD mortality decreased by 31.6% from 1990 to 2022. Of the 21 regions, North Africa and Middle East ranked 3rd in 1990 and 5th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 654.8 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 3,914.0 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	2,764,881	9,411	420.5	1.9	82.2
Ischemic heart disease	29,397,709	770,738	5,780.2	196.2	4,028.1
Ischemic stroke	4,390,907	254,063	803.4	71.8	1,267.9
Intracerebral hemorrhage	1,207,552	112,756	199.2	26.0	631.2
Subarachnoid hemorrhage	660,160	12,513	115.1	2.8	86.9
Hypertensive heart disease	1,043,500	136,843	240.0	38.0	654.8
Non-rheumatic calcific aortic valve disease	260,404	3,603	56.9	0.9	20.0
Non-rheumatic degenerative mitral valve disease	271,543	3,108	63.3	0.7	18.2
Other non-rheumatic valve diseases	3,516	338	0.6	0.1	2.0
Myocarditis	33,842	3,336	5.8	0.8	22.0
Alcoholic cardiomyopathy	3,065	124	0.5	<0.1	0.8
Other cardiomyopathy	311,277	7,084	52.1	1.5	53.3
Pulmonary arterial hypertension	11,860	1,459	2.0	0.3	11.6
Atrial fibrillation and flutter	1,560,144	11,850	397.3	4.0	78.6
Aortic aneurysm	Not estimated	4,152	Not estimated	1.0	21.5
Lower extremity peripheral arterial disease	3,580,213	1,941	876.0	0.5	13.8
Endocarditis	17,388	2,628	3.0	0.6	17.4
Other cardiovascular and circulatory diseases	8,613,986	30,165	1,640.6	7.2	271.6

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

Deaths

(Rate)

15.0

147.1

34.4

36.8

4.0

15.9

0.9

0.4

<0.1

0.3

0.1

5.2

03

32

1.0

0.3

0.8

2.4

Prevalence

(Rate)

692.5

2.214.6

838.0

242.9

85.1

111.8

25.1

35.6

<0.1

6.5

0.7

48.7

17

5896

798.3

2.8

7074

Not estimated

Disability-Adjusted

Life Years (DALYs, Rate)

466.1

3,285.4

678.0

902.9

126.8

285.1

16.0

91

0.4

14 2

3.0

83

847

19.0


9.3

23.5

94.3

136.8

## Cardiovascular Disease in South Asia FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY



Female Male 95 plu 90 to 94 85 to 89 80 to 84 75 to 79 70 to 74 65 to 69 60 to 64 55 to 59 50 to 54 eby 45 to 49 40 to 44 35 to 39 30 to 34 25 to 29 20 to 24 5 to 19 Under 10,000 5.000 10,000 Cardiovascular Disease Mortality Rate per 100,000 1990 2022

Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Results, uncertainty intervals, and methods available online.






Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in East Asia** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in East Asia ranged from 91.8 to 352.9 per 100,000 in 2022; a 3.8 fold difference. CVD mortality decreased by 32.4% from 1990 to 2022. Out of the 21 regions, East Asia was ranked 7th in 1990 and 11th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest agestandardized DALYs in 2022 at 269.3 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 2,745.2 per 100,000.






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification





Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Years (DALYs, Rate) Туре (Count) (Count) (Rate) (Rate) Rheumatic heart disease 5,266,540 75,927 343.8 3.7 89.1 Ischemic heart disease 68.751.838 2.099.130 3,183.8 108.4 1.917.9 Ischemic stroke 23,266,169 1,139,094 1,064.1 57.0 1,072.0 Intracerebral hemorrhage 4,923,009 1.433.592 239.3 68.6 1,361.0 Subarachnoid hemorrhage 1.720.413 91.177 85.9 4.3 111.1 331,523 189.0 17.4 269.3 Hypertensive heart disease 4,114,002 Non-rheumatic calcific 751.611 1.805 33.5 2.2 0.1 aortic valve disease Non-rheumatic degenerative mitral valve disease 2,832,655 1,066 125 3 01 29 Other non-rheumatic valve 1.382 247 0.1 <0.1 0.3 diseases 165.695 9,139 11 0 0.5 175 Mvocarditis Alcoholic cardiomyopathy 32,864 1,551 1.8 0.1 2.8 280,309 19.1 0.7 20.0 Other cardiomyopathy 12.430 Pulmonary arterial 42 191 6.687 22 03 77 hypertension Atrial fibrillation and flutter 12.179.180 67.436 5516 40 881 Aortic aneurysm Not estimated 11,241 Not estimated 0.5 14.3 Lower extremity peripheral 27,223,946 1,197.4 0.1 8.3 2.326 arterial disease 3.171 37.262 2.2 0.2 4.8 Endocarditis Other cardiovascular and 6.009.279 12.839 290.8 0.7 31.2 circulatory diseases

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.






Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

### **Cardiovascular Disease in Oceania** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington





Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

# **Cardiovascular Disease in Southeast Asia** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY



2022 Age-Standardized CVD Mortality Per 100,000	
57.5 - 108.2 259.1 - 287.6	
108.3 - 147.4 🚺 287.7 - 329.4	
147.5 - 194.0 🚺 329.5 - 379.6	- 💓 💎 🏹 👘
194.1 - 228.3 379.7 - 441.4	
228.4 - 259.0 441.5 - 714.5	and the second s

Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Years (DALYs, Rate) Туре (Count) (Count) (Rate) (Rate) Rheumatic heart disease 5,706,614 11,882 769.9 1.7 113.3 Ischemic heart disease 31.693.855 656.205 4.589.4 110.7 2,501.3 Ischemic stroke 9,373,197 325,362 1,358.5 63.4 1,239.7 Intracerebral hemorrhage 3.334.389 526.960 441.4 82.5 2,002.4 Subarachnoid hemorrhage 1,194,567 38.419 158.1 6.0 186.6 1,017,714 132,805 168.1 22.9 458.5 Hypertensive heart disease Non-rheumatic calcific 157.395 5.1 1.425 25.6 0.3 aortic valve disease Non-rheumatic degenerative mitral valve disease 513,144 635 84.3 0.1 37 Other non-rheumatic valve 271 62 <0.1 <0.1 0.2 diseases 44.350 1.369 6.5 0.3 7.6 Mvocarditis Alcoholic cardiomyopathy 3,649 333 0.5 <0.1 1.7 2.7 62.7 Other cardiomyopathy 163.221 14.967 26.4 Pulmonary arterial 13 615 661 19 0.1 40 hypertension Atrial fibrillation and flutter 3.614.518 23.517 5976 54 1094 Aortic aneurysm Not estimated 7,031 Not estimated 1.3 23.3 Lower extremity peripheral 7,493,846 821 1,195.2 9.8 0.1 arterial disease Endocarditis 37.970 7.559 1.2 35.5 6.1 Other cardiovascular and circulatory diseases 2,746,132 8.101 410 2 1.3 60.1

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in Central Sub-Saharan Africa** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY





Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification






Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

## **Cardiovascular Disease in Eastern Sub-Saharan Africa** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Eastern Sub-Saharan Africa ranged from 187.8 to 410.8 per 100,000 in 2022; a 2.2 fold difference. CVD mortality decreased by 23.6% from 1990 to 2022. Of the 21 regions, Eastern Sub-Saharan Africa ranked 10th in 1990 and 12th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 676.3 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 3,193.0 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	5,548,728	6,452	1,295.3	3.8	153.1
Ischemic heart disease	6,423,413	109,091	3,169.3	77.6	1,664.7
Ischemic stroke	2,297,408	61,695	1,147.3	54.1	997.6
Intracerebral hemorrhage	734,889	114,782	270.5	72.4	1,671.9
Subarachnoid hemorrhage	213,645	5,213	78.6	2.6	85.7
Hypertensive heart disease	512,396	46,238	349.8	36.4	676.3
Non-rheumatic calcific aortic valve disease	23,487	1,206	13.8	0.9	16.8
Non-rheumatic degenerative mitral valve disease	22,598	1,266	13.0	0.7	17.9
Other non-rheumatic valve diseases	273	23	0.1	<0.1	0.3
Myocarditis	18,811	365	5.5	0.1	5.4
Alcoholic cardiomyopathy	9,559	3	3.1	<0.1	0.3
Other cardiomyopathy	498,218	8,394	161.4	3.8	134.5
Pulmonary arterial hypertension	6,099	453	2.1	0.2	6.4
Atrial fibrillation and flutter	578,307	3,044	400.7	3.2	71.7
Aortic aneurysm	Not estimated	2,549	Not estimated	1.7	35.8
Lower extremity peripheral arterial disease	933,431	1,280	675.1	1.1	21.9
Endocarditis	33,390	4,027	7.0	1.9	57.3
Other cardiovascular and circulatory diseases	2,582,036	5,139	1,283.6	2.7	135.9

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

Deaths

(Rate)

2.5

81.5

58.6

Prevalence

(Rate)

847.1

2.992.7

1,339.5

Disability-Adjusted

Life Years

1,680.0

1,038.3

133.9

(DALYs, Rate)

### Cardiovascular Disease in Southern Sub-Saharan Africa FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification





26.826 206.0 49.0 1,166.8 54.0 2.0 63.1 21,221 153.2 47.1 839.6 23.1 22.0 1.3 12.4 0.4 11.6 <0.1 <0.1 0.4 5.9 0.1 6.3 0.5 <0.1 0.2 91.0 12.1 276.7 23 01 39 5109 4.2 894 Not estimated 2.5 50.5 973.7 42.8 2.0 0.9 33.3 4.1 2.458.0 4.7 225.9

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

### **Cardiovascular Disease in Western Sub-Saharan Africa** FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Western Sub-Saharan Africa ranged from 238.1 to 449.7 per 100,000 in 2022; a 1.9 fold difference. CVD mortality decreased by 19.9% from 1990 to 2022. Of the 21 regions, Western Sub-Saharan Africa ranked 9th in 1990 and 8th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 593.8 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 3,330.4 per 100,000






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification





Disability-Adjusted Cardiovascular Disease Prevalent Cases Deaths Prevalence Deaths Life Year Туре (Count) (Count) (Rate) (Rate) (DALYs, Rate) Rheumatic heart disease 4,640,580 5,175 963.3 2.3 108.1 Ischemic heart disease 7.452.708 144.797 3.228.8 94.4 1,824.3 3,203,095 82,875 1,240.4 60.9 1,114.1 Ischemic stroke Intracerebral hemorrhage 1.065.970 118.256 336.7 62.8 1,478.2 Subarachnoid hemorrhage 230.618 5.777 73.8 2.5 81.3 47,933 289.7 29.3 593.8 Hypertensive heart disease 496,314 Non-rheumatic calcific 24.823 1.650 11.3 19.3 1.1 aortic valve disease Non-rheumatic degenerative mitral valve disease 28,895 1.077 13.0 0.6 13.0 Other non-rheumatic valve 220 27 0.1 <0.1 0.3 diseases 26.383 478 6.1 0.1 5.8 Mvocarditis Alcoholic cardiomyopathy 10.332 139 3.1 0.1 2.1 312,714 83.9 8.2 204.8 Other cardiomyopathy 16.486 Pulmonary arterial 9646 444 30 01 54 hypertension Atrial fibrillation and flutter 809.397 4.749 474 5 4.6 884 Aortic aneurysm Not estimated 3,377 Not estimated 2.0 40.0 Lower extremity peripheral 1,166,933 708.6 23.1 1.641 1.3 arterial disease 25.587 3.241 5.3 39.6 Endocarditis 1.4 Other cardiovascular and 5.350.530 14.280 2.502.3 7.4 293.3 circulatory diseases

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, loess line in blue with shaded 95% uncertainty interval.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Institute for Health Metrics and Evaluation - National Heart, Lung, and Blood Institute - American College of Cardiology Foundation

Global Burden of Cardiovascular Diseases and Risks Collaboration

Data from Global Burden of Disease Study, Institute for Health Metrics and Evaluation, University of Washington

#### AGGREGATE CAUSE: CARDIOVASCULAR DISEASE




Figure 1. Global map of age-standardized cardiovascular disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 4. Global cardiovascular disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### **RHEUMATIC HEART DISEASE**




Figure 1. Global map of age-standardized rheumatic heart disease mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global rheumatic heart disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Rheumatic heart disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global rheumatic heart disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### **ISCHEMIC HEART DISEASE**




Figure 1. Global map of age-standardized ischemic heart disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global ischemic heart disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 4. Global ischemic heart disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### AGGREGATE CAUSE: STROKE




Figure 1. Global map of age-standardized stroke mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global stroke estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Female Male

4,000

Age-Standardized DALYs per 100,000

1,000

Figure 4. Global stroke age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### **ISCHEMIC STROKE**




Figure 1. Global map of age-standardized ischemic stroke mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global ischemic stroke estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 4. Global ischemic stroke age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### **INTRACEREBRAL HEMORRHAGE**




Figure 1. Global map of age-standardized intracerebral hemorrhage mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global intracerebral hemorrhage estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Intracerebral hemorrhage age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global intracerebral hemorrhage age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### SUBARACHNOID HEMORRHAGE




Figure 1. Global map of age-standardized subarachnoid hemorrhage mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global subarachnoid hemorrhage estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Subarachnoid hemorrhage age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global subarachnoid hemorrhage age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### HYPERTENSIVE HEART DISEASE




Figure 1. Global map of age-standardized hypertensive heart disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global hypertensive heart disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Hypertensive heart disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global hypertensive heart disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### AGGREGATE CAUSE: NON-RHEUMATIC VALVULAR HEART DISEASE




Figure 1. Global map of age-standardized non-rheumatic valvular heart disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global non-rheumatic valvular heart disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Non-rheumatic valvular heart disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global non-rheumatic valvular heart disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### NON-RHEUMATIC CALCIFIC AORTIC VALVE DISEASE




Figure 1. Global map of age-standardized non-rheumatic calcific aortic valve disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global non-rheumatic calcific aortic valve disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Non-rheumatic calcific aortic valve disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global non-rheumatic calcific aortic valve disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### NON-RHEUMATIC DEGENERATIVE MITRAL VALVE DISEASE




Figure 1. Global map of age-standardized non-rheumatic degenerative mitral valve disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global non-rheumatic degenerative mitral valve disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Non-rheumatic degenerative mitral valve disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global non-rheumatic degenerative mitral valve disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### OTHER NON-RHEUMATIC VALVE DISEASES




Figure 1. Global map of age-standardized other non-rheumatic valve diseases mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global other non-rheumatic valve diseases estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Other non-rheumatic valve diseases age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global other non-rheumatic valve diseases age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### AGGREGATE CAUSE: CARDIOMYOPATHY AND MYOCARDITIS




Figure 1. Global map of age-standardized cardiomyopathy and myocarditis mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiomyopathy and myocarditis estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiomyopathy and myocarditis age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiomyopathy and myocarditis age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# **MYOCARDITIS**




Figure 1. Global map of age-standardized myocarditis mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global myocarditis estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 4. Global myocarditis age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# ALCOHOLIC CARDIOMYOPATHY




Figure 1. Global map of age-standardized alcoholic cardiomyopathy mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global alcoholic cardiomyopathy estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Alcoholic cardiomyopathy age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global alcoholic cardiomyopathy age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

## **OTHER CARDIOMYOPATHY**




Figure 1. Global map of age-standardized other cardiomyopathy mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global other cardiomyopathy estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Other cardiomyopathy age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global other cardiomyopathy age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# PULMONARY ARTERIAL HYPERTENSION




Figure 1. Global map of age-standardized pulmonary arterial hypertension mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global pulmonary arterial hypertension estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Pulmonary arterial hypertension age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global pulmonary arterial hypertension age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# ATRIAL FIBRILLATION AND FLUTTER




Figure 1. Global map of age-standardized atrial fibrillation and flutter mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global atrial fibrillation and flutter estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Atrial fibrillation and flutter age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global atrial fibrillation and flutter age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

## **AORTIC ANEURYSM**




Figure 1. Global map of age-standardized aortic aneurysm mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global aortic aneurysm estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 4. Global aortic aneurysm age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE




Figure 1. Global map of age-standardized lower extremity peripheral arterial disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global lower extremity peripheral arterial disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022






Figure 3. Lower extremity peripheral arterial disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar





## **ENDOCARDITIS**




Figure 1. Global map of age-standardized endocarditis mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global endocarditis estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Rate per 100,000

Figure 4. Global endocarditis age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# OTHER CARDIOVASCULAR AND CIRCULATORY DISEASES




Figure 1. Global map of age-standardized other cardiovascular and circulatory diseases mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global other cardiovascular and circulatory diseases estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Other cardiovascular and circulatory diseases age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global other cardiovascular and circulatory diseases age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# AMBIENT PARTICULATE MATTER POLLUTION




Figure 1. Global map of cardiovascular disease mortality attributable to ambient particulate matter pollution per 100,000 in 2022 with equal interval classification






Figure 2. Global cardiovascular disease attributable to ambient particulate matter pollution estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022





# HOUSEHOLD AIR POLLUTION FROM SOLID FUELS




Figure 1. Global map of cardiovascular disease mortality attributable to household air pollution from solid fuels per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to household air pollution from solid fuels estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to household air pollution from solid fuels per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to household air pollution from solid fuels per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### **HIGH TEMPERATURE**




Figure 1. Global map of cardiovascular disease mortality attributable to high temperature per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high temperature estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high temperature per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high temperature per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### LOW TEMPERATURE




Figure 1. Global map of cardiovascular disease mortality attributable to low temperature per 100,000 in 2022 with equal interval classification






Figure 2. Global cardiovascular disease attributable to low temperature estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022





0,00

400

60 60

300

100

200

Under

5,00

-00 \*:00

Under 5

2000

,00**-**

ò

3000 -00

# LEAD EXPOSURE




Figure 1. Global map of cardiovascular disease mortality attributable to lead exposure per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to lead exposure estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to lead exposure per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to lead exposure per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# SMOKING




Figure 1. Global map of cardiovascular disease mortality attributable to smoking per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to smoking estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 4. Global cardiovascular disease age-specific estimates attributable to smoking per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

### SECONDHAND SMOKE




Figure 1. Global map of cardiovascular disease mortality attributable to secondhand smoke per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to second hand smoke estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to secondhand smoke per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to secondhand smoke per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# **HIGH ALCOHOL USE**




Figure 1. Global map of cardiovascular disease mortality attributable to high alcohol use per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high alcohol use estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high alcohol use per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high alcohol use per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

# **DIETARY RISKS**




Figure 1. Global map of cardiovascular disease mortality attributable to dietary risks per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to dietary risks estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 4. Global cardiovascular disease age-specific estimates attributable to dietary risks per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

## LOW PHYSICAL ACTIVITY




Figure 1. Global map of cardiovascular disease mortality attributable to low physical activity per 100,000 in 2022 with equal interval classification





Figure 2. Global cardiovascular disease attributable to low physical activity estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to low physical activity per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to low physical activity per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

## HIGH FASTING PLASMA GLUCOSE




Figure 1. Global map of cardiovascular disease mortality attributable to high fasting plasma glucose per 100,000 in 2022 with equal interval classification





Figure 2. Global cardiovascular disease attributable to high fasting plasma glucose estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



#### Rate per 100,000

Figure 4. Global cardiovascular disease age-specific estimates attributable to high fasting plasma glucose per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### HIGH LDL CHOLESTEROL




Figure 1. Global map of cardiovascular disease mortality attributable to high LDL cholesterol per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high LDL cholesterol estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high LDL cholesterol per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high LDL cholesterol per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

## HIGH SYSTOLIC BLOOD PRESSURE




Figure 1. Global map of cardiovascular disease mortality attributable to high systolic blood pressure per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high systolic blood pressure estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 4. Global cardiovascular disease age-specific estimates attributable to high systolic blood pressure per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

## **HIGH BODY MASS INDEX**




Figure 1. Global map of cardiovascular disease mortality attributable to high body mass index per 100,000 in 2022 with equal interval classification





Figure 2. Global cardiovascular disease attributable to high body mass index estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high body mass index per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high body mass index per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

#### **KIDNEY DYSFUNCTION**




Figure 1. Global map of cardiovascular disease mortality attributable to kidney dysfunction per 100,000 in 2022 with equal interval classification






Figure 2. Global cardiovascular disease attributable to kidney dysfunction estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022





Summary of Global Burden of Disease Study Methods

# Background

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is a multinational collaborative research study with over 10,000 collaborators around the world. GBD generates a time series of summary measures of health, including prevalence, cause-specific mortality (CSMR), years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) to provide a comprehensive view of health burden for a wide range of stakeholders including clinicians, public and private health systems, ministries of health, and other policymakers. These estimates are produced for 371 causes of death and 88 risk factors according to mutually exclusive, collectively exhaustive hierarchies of health conditions and risks. The study is led by a principal investigator and governed by a study protocol, with oversight from a Scientific Council, and an Independent Advisory Committee.<sup>1</sup> GBD is performed in compliance with Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).<sup>2</sup> GBD uses de-identified data, and the waiver of informed consent was reviewed and approved by the University of Washington Institutional Review Board (study number 9060).

This almanac presents results for 18 cardiovascular diseases (CVD) and the CVD burden attributed to 15 risk factors (including an aggregate grouping of dietary risks) by GBD region. A summary of methods follows. Additional information can be found online at <a href="https://ghdx.healthdata.org/record/ihme-data/cvd-1990-2022">https://ghdx.healthdata.org/record/ihme-data/cvd-1990-2022</a>, including:

- Detailed methods, including information on the GBD location hierarchy, the GBD cause hierarchy, mapping of International Classification of Disease (ICD) codes to the GBD cause list, and health states and associated disability weights used in the comorbidity simulation.
- 2) Mean values and 95% uncertainty intervals for all estimates presented in the almanac, by country, sex, age group, and year.
- 3) Cause-specific write-ups outlining methods for estimation of mortality with details of model parameters for each cause, including selection of location-specific covariates.
- Cause-specific write-ups outlining methods for estimation of prevalence, with details of systematic reviews, input data, all data adjustments, modeling frameworks, and model parameter selection.
- 5) Risk factor write-ups containing details of systematic reviews, input data, all data adjustments, modeling frameworks, and model parameter selection.
- 6) Documentation of compliance with GATHER

# Methods

## Demographic groupings

This study estimated CVD burden for 204 countries and territories grouped into 21 regions and seven super-regions. GBD regions are made up of countries and territories that are geographically close and epidemiologically similar. GBD regions are grouped into super-regions based on observed cause of death patterns. Estimates presented in this almanac were produced at the subnational level (e.g., region, state, or province) for a subset of locations including Brazil, China, Ethiopia, India, Indonesia, Italy, Iran, Japan, Kenya, Mexico, Nigeria, Norway, Pakistan, the Philippines, Russia, South Africa, the UK, and the USA. Since GBD 2019, the GBD location hierarchy has included all WHO member states. Each epidemiological quantity of interest was estimated for 23 age groups from birth to 95 years and older; males, females, and both sexes combined from 1990 to 2022. Age standardization used the direct method with the GBD standard global population age structure. This standard population is determined by using the population structure of all national locations with a population greater than 5 million people. First, the

proportion of the location-specific population in each age group is calculated. Second, these age-specific proportions are averaged across all locations.<sup>3</sup>

## Sociodemographic index

Results are also presented by Socio-demographic Index (SDI) value. SDI is a composite measure of overall development comprised of lag-distributed income per capita (LDI), average years of education, and fertility rates among females younger than 25 years (TFU25). LDI and education are positively correlated with improved health outcomes, while TFU25 is negatively correlated. SDI is thus calculated as the geometric mean of LDI, education, and the inverse of TFU25.<sup>3</sup>

## Cardiovascular Disease Case Definitions

A set of case definitions was used to consistently identify and harmonize data on cardiovascular diseases for all locations across the entire time period. CVD case definitions used by GBD are shown in Table 1. Of note, heart failure is classified as an impairment rather than an underlying cause of death in the GBD classification system. Heart failure is a structural or functional abnormality of the heart which impairs cardiac filling and output and, within the GBD, contributes burden to many underlying causes of death including all cardiovascular diseases listed below with the exception of aortic aneurysm and lower extremity peripheral arterial disease. GBD relies on data in which heart failure has been diagnosed by clinicians using structured criteria, such as the Framingham, European Society of Cardiology, or Universal Definition and Classification of Heart Failure criteria. Prevalent heart failure is defined as structural heart disease with current or previous symptoms of heart failure (ACCF/AHA stages C or D).<sup>4</sup> As part of the GBD estimation process, heart failure burden is included in the burden estimates for each etiologic underlying cause of death.

## All-cause mortality and population estimates

GBD produces estimates of all-cause mortality and population; for cause-specific burden, these are integral inputs into the cause-specific estimation process. Detailed methods have been previously reported.<sup>3</sup>

## Cause-specific mortality

Death records, including vital registration for all cardiovascular causes and verbal autopsy data for total cardiovascular disease, ischemic heart disease, and total stroke, were mapped to the GBD cause list. Records where the underlying cause was considered nonspecific, intermediate, or implausible were reassigned to a valid underlying cause of death via redistribution algorithms which utilized proportional information, cause-specific priors, or data sets with information on all contributing causes of death in addition to the underlying cause.<sup>5</sup> A counterfactual approach, based on data from 2014-2019, was used to estimate excess cause-specific deaths in 2020 and 2021 and reclassify them as deaths due to COVID-19. A noise reduction algorithm was applied to mortality data and a Bayesian geospatial ensemble regression model (CODEm, the cause of death ensemble model, Institute for Health Metrics and Evaluation (IHME), Seattle, Washington) was used with location-specific covariates to produce smoothed time series for each location, including where data was sparse or missing.<sup>6</sup> Individual models included in the ensemble are weighted according to performance on out-of-sample predictive validity testing.

## CoDCorrect

As each cause-specific model is estimated separately, the sum of these models is not certain to equal the all-cause mortality estimates. The CoDCorrect process rescales each level of the GBD cause hierarchy such that the sum of the cause-specific estimates does not exceed the all-cause mortality estimates.<sup>6</sup> Using the GBD cause hierarchy, this process begins by rescaling the Level 1 causes to match the all-cause

mortality estimates. Level 2 causes are then rescaled to their corrected parent cause estimates. This process continues for Level 3 and Level 4 causes such that all levels of the hierarchy are rescaled.

#### Prevalence

Prevalence was estimated for each disease using the Disease Model—Bayesian meta-regression (DisMod-MR 2.1 (IHME, Seattle, Washington)) an epidemiologic state-transition disease modeling tool. DisMod-MR evaluates all available high-quality, population-representative data for disease incidence, prevalence, remission, and mortality, while enforcing consistency between these various parameters.<sup>6</sup> Possible input data sources included scientific literature identified via systematic reviews of published literature and expert review, population surveys, and administrative health facility data. Where applicable, network meta-analysis was performed using the meta-regression—Bayesian, regularised, trimmed software (MR-BRT, IHME, Seattle, Washington) to allow adjustment for study-level differences in case definition or measurement method.<sup>7</sup> If necessary, correction factors were calculated to adjust tabulated inpatient-only health facility data to account for readmission, non-primary diagnoses, and outpatient visits.

## **Risk factors**

Definitions used for each risk factor can be found in Table 2.

# Attributable burden estimation.

The GBD estimates disease burden attributable to risk factors using a comparative risk assessment framework.<sup>8</sup>

Population-level exposure to each risk factor was estimated using statistical models. Most risk exposure was estimated using spatiotemporal Gaussian process regression (ST-GPR) or DisMod-MR, described above. ST-GPR is a geospatial Gaussian process regression model which borrows strength between locations and over time to generate estimates of mean risk factor exposures.<sup>8</sup> Input data sources included scientific literature identified via systematic reviews of published literature and expert review, population health surveys, and for ambient air pollution, satellite data. Person-level data from cohort studies were used to determine the standard deviation of the risk factor exposure and to estimate the shape of the exposure distribution.

Each risk was assigned outcomes from the GBD study list of diseases to form risk-outcome pairs based on the availability of convincing or probable evidence of a disease-risk association. For each risk factor, the level of exposure where disease risk is minimized, or theoretical minimum risk exposure level (TMREL) was determined.

Relative risks were estimated for each risk outcome pair following the Burden of Proof (BoP) method, previously reported.<sup>9</sup> Briefly, following PRISMA guidelines, systematic reviews were performed for studies reporting relative risk or hazard ratios, and data were extracted using a standardized template.<sup>10</sup> Using MR-BRT, the relative risk between risk and disease outcome was modeled, integrating over the exposure ranges reported. This approach allows us to identify publication or reporting bias and to account for between-study heterogeneity and within-study correlation. An example of this approach has been reported in detail for the relationship between systolic blood pressure and ischemic heart disease.<sup>11</sup>

Population-attributable fractions (PAF) were then calculated for each risk-outcome pair using the exposure levels, the estimated relative risk, and the TMREL to generate the amount of burden for each

disease due to risk factor exposure. Attributable burden was then estimated as the PAF for that riskoutcome pair multiplied by the burden measure of interest.

#### Summary measures of disease burden

Years lived with disability (YLDs) were estimated by multiplying disease prevalence by the relevant disability weight after accounting for comorbidity in a simulation process.<sup>6</sup> Disability weights, which represent the magnitude of health loss associated with the outcome were constructed based on surveys of the general population, with a statistical adjustment made to account for comorbidity. Years of life lost (YLLs) due to premature mortality were computed by multiplying the number of estimated deaths by the standard life expectancy at age of death.<sup>6</sup> The standard life expectancy was determined by using the lowest observed age-specific mortality rates by location and sex across all estimation years from locations with total populations greater than 5 million in 2016 to establish a theoretical minimum risk reference life table. Disability-adjusted life years (DALYs) were calculated as the sum of YLLs and YLDs and represent the total health burden associated with each cause. All summary measures were estimated using 500 draws and uncertainty intervals were determined as the 2.5<sup>th</sup> and 97.5<sup>th</sup> values of the posterior distribution of model draws.

#### References

1. Murray CJL. PROTOCOL FOR THE GLOBAL BURDEN OF DISEASES, INJURIES, AND RISK FACTORS STUDY (GBD).

2. Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *The Lancet*. 2016;388:e19–e23.

3. Wang H, Abbas KM, Abbasifard M, et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020;396:1160–1203.

4. Anon. Universal Definition and Classification of Heart Failure: A Step in the Right Direction from Failure to Function - American College of Cardiology Accessed November 8, 2023. https://www.acc.org/Latest-in-Cardiology/Articles/2021/07/12/12/31/Universal-Definition-and-Classification-of-Heart-Failure.

5. Anon. Public health utility of cause of death data: applying empirical algorithms to improve data quality | BMC Medical Informatics and Decision Making | Full Text Accessed November 8, 2023. https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-021-01501-1.

6. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020;396:1204–1222.

7. Zheng P, Barber R, Sorensen RJD, Murray CJL, Aravkin AY. Trimmed Constrained Mixed Effects Models: Formulations and Algorithms. *Journal of Computational and Graphical Statistics*. 2021;30:544–556. 8. Anon. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Accessed November 8, 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30752-2/fulltext.

9. Zheng P, Afshin A, Biryukov S, et al. The Burden of Proof studies: assessing the evidence of risk. *Nat Med*. 2022;28:2038–2044.

10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Systematic Reviews*. 2021;10:89.

11. Razo C, Welgan CA, Johnson CO, et al. Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. *Nat Med*. 2022;28:2056–2065.

12. Rwebembera J, Marangou J, Mwita JC, et al. 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease. *Nat Rev Cardiol*. 2023:1–14.

Anon. Fourth Universal Definition of Myocardial Infarction (2018) | Circulation Accessed November
9, 2023. https://www.ahajournals.org/doi/10.1161/CIR.000000000000617.

14. Jones WB, Riley CP, Reeves TJ, Sheffield LT. Natural history of coronary artery disease. *Bull N Y Acad Med*. 1972;48:1109–1125.

15. Raff GL, Chair, Abidov A, et al. SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. *Journal of Cardiovascular Computed Tomography*. 2009;3:122–136.

16. Donkor ES. Stroke in the 21st Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. *Stroke Res Treat*. 2018;2018:3238165.

17. Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. *Bull World Health Organ*. 1980;58:113–130.

18. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;143:e72–e227.

19. Ammirati E, Frigerio M, Adler ED, et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. *Circulation: Heart Failure*. 2020;13:e007405.

20. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016;37:67–119.

21. Iwasaki Y, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. *Circulation*. 2011;124:2264–2274.

22. Saleh K, Haldar S. Atrial fibrillation: a contemporary update. *Clinical Medicine*. 2023;23:437–441.

23. Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;146:e334–e482.

24. Criqui MH, Matsushita K, Aboyans V, et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. *Circulation*. 2021;144:e171–e191.

25. Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria. *Clin Infect Dis*. 2023;77:518–526.

Table 1: Cardiovascular case definitions

<u>GBD Cause</u>	Definition			
Rheumatic heart disease	Diagnosis by a physician with use of echocardiography. This case definition for			
	echocardiographic confirmation of rheumatic heart disease follows the World Heart			
	Federation criteria for echocardiographic diagnosis <sup>12</sup>			
Ischemic heart disease	1) Myocardial infarction as defined in the Fourth Universal Definition of Myocardial Infarction <sup>13</sup>			
	2) Coronary artery disease defined as At least moderate (>50%) stenosis of an epicardial coronary vessel based on angiographic or functional diagnostic testing <sup>14, 15</sup>			
	3) Heart failure due to ischemic heart disease defined as a clinical diagnosis based on structured criteria described above <sup>4</sup>			
Ischemic stroke	Brain imaging showing blood flow to part of the brain being occluded and according to WHO criteria of rapidly developing clinical signs of disturbance of cerebral function lastin >24 hours or leading to death <sup>16, 17</sup>			
Intracerebral hemorrhage	Brain imaging showing bleeding into the tissue of the brain and according to WHO criter of rapidly developing clinical signs of disturbance of cerebral function lasting >24 hours of leading to death. Only non-traumatic events were included <sup>16, 17</sup>			
Subarachnoid hemorrhage	Brain imaging or lumbar puncture indicating the rupture of a blood vessel resulting in bleeding into the subarachnoid space and according to WHO criteria of rapidly developing clinical signs of disturbance of cerebral function lasting >24 hours or leading to death. Only non-traumatic events were included <sup>16, 17</sup>			
Hypertensive heart disease	Heart condition caused by long-term high blood pressure, resulting in left ventricular hypertrophy, diastolic dysfunction, and clinical heart failure with either preserved or reduced systolic function of the left ventricle. Clinical diagnosis of heart failure is based structured criteria described above <sup>4</sup>			
Non-rheumatic calcific aortic valve disease	Diagnosis by a physician based on echocardiographic findings of stenosis or regurgitation caused by progressive calcification of the valve, excluding congenital, rheumatic, or infectious causes but including stenosis of a bicuspid aortic valve <sup>18</sup>			
Non-rheumatic mitral valve disease	Diagnosis by a physician based on echocardiographic findings of myxomatous degeneration or prolapse of the mitral valve leading to at least moderate mitral regurgitation, excluding disease due to annular dilation, congenital, rheumatic, or infectious causes <sup>18</sup>			
Other non-rheumatic valve disease	Residual category capturing diagnosis by a physician based on echocardiographic findings of stenosis or regurgitation of pulmonary and tricuspid valves. Valve dysfunction due to congenital, infectious, or rheumatic causes was estimated separately <sup>18</sup>			
Myocarditis	Acute myocarditis is defined by symptoms, clinical exam, cardiac imaging such as cardiac MRI or endomyocardial biopsy <sup>19</sup>			
	Heart failure due to myocarditis is a clinical diagnosis of heart failure based on structured criteria described above with a history of myocarditis <sup>4</sup>			
Alcoholic cardiomyopathy	Clinical diagnosis of heart failure based on structured criteria described above due to the toxic effects of ingested alcohol <sup>4</sup>			
Other cardiomyopathy	Residual category capturing a clinical diagnosis of heart failure based on structured criteri described above without a history of other potential causes of heart failure <sup>4</sup>			
Pulmonary arterial	Diagnosis by a physician based on findings of restricted blood flow and elevated pressure			
hypertension	in the pulmonary arteries based on right heart catheterization or echocardiography <sup>20</sup>			
Atrial fibrillation and flutter	ECG studies demonstrating irregularly irregular RR intervals; and no P waves <sup>21, 22</sup>			
Aortic aneurysm	Abdominal or thoracic aorta is abnormally enlarged and weakened due to atherosclerosis			
	high blood pressure, or inflammation, which can lead to tearing or rupture of the blood vessel <sup>23</sup> Prevalence and YLDs are not currently estimated for aortic aneurysm			
Lower extremity peripheral	An ankle-brachial index (ABI) less than or equal to 0.90 <sup>24</sup>			

Endocarditis	Acute infective endocarditis was diagnosed defined as a clinical diagnosis clinically via based on the Duke Criteria which includes confirmation through clinical signs and blood tests <sup>25</sup>	
	Heart failure due to endocarditis was based on a clinical diagnosis of heart failure based on structured criteria described above with a history of acute infective endocarditis <sup>4</sup>	
Other cardiovascular and	This aggregate cause incorporates less common cardiovascular diseases that are not	
circulatory diseases	modelled independently, for example pericarditis. Diagnostic criteria vary based on the	
	underlying condition.	

Risk factor	Definition				
High systolic blood pressure	Brachial SBP greater than 105 to 115 mm Hg				
High LDL cholesterol	LDL-cholesterol greater than 0.9 to 1.4 mmol/L				
High body mass index	Body mass index greater than 20 to 23 kg/m <sup>2</sup>				
High fasting plasma glucose	Serum fasting plasma glucose greater than 4.9 to 5.3 mmol/L				
Kidney dysfunction	Estimated glomerular filtration rate less than 60 ml/min/1.73m <sup>2</sup> and/or albumin to				
	creatinine ratio less than or equal to 30 mg/g.				
Ambient particulate matter	Population-weighted annual average mass concentration of PM2.5 in a cubic meter of a				
pollution	greater than 2.4 $\mu$ g/m <sup>3</sup> to 5.9 $\mu$ g/m <sup>3</sup>				
Household air pollution from	Proportion of individuals using solid cooking fuels and the level of PM2.5 air pollution				
solid fuels	exposure for these individuals greater than 2.4 ug/m <sup>3</sup> to 5.9 ug/m <sup>3</sup>				
High temperature	Exposure to temperatures warmer than the temperature associated with the lowest				
	overall mortality attributable to the risk, in a given location and year.				
Low temperature	Exposure to temperatures colder than the temperature associated with the lowest overall				
	mortality attributable to the risk, in a given location and year.				
Lead exposure	Micrograms of lead per gram of bone greater than the age-specific TMREL				
Dietary risks	Composite risk factor consisting of suboptimal exposure to dietary factors including fruit,				
	vegetables, whole grains, nuts and seeds, fiber, omega-3 fatty acids, polyunsaturated fatty				
	acids, calcium, milk, legumes, red meat, processed meat, sugar-sweetened beverages,				
	trans fatty acids, and sodium.				
Smoking	Current or former users of any smoked tobacco product on a daily or occasional basis				
Secondhand smoke	Current exposure of non-smokers to secondhand tobacco smoke at home, at				
	work, or in other public places				
High alcohol use	Grams per day of pure alcohol consumed among current drinkers greater than the age-,				
	sex-, and region-specific TMREL				
Low physical activity	Physical activity performed by adults older than 25 years of age, for at least ten minutes a				
	a time, across all domains of life (leisure/recreation, work/household and transport) less				
	than 3000-4500 metabolic equivalent-minutes per week.				

Table 2.	Rick	factor	exposure	definition
Table 2.	RISK	Tactor	exposure	uemilion